Acquisition adds expertise in virus, mycoplasma and bacteria testing and strengthens Millipore’s growing services business

BILLERICA, Mass–July 5, 2005–Millipore Corporation (NYSE:MIL) today announced it has completed the acquisition of MicroSafe, B.V., for approximately $9.3M. MicroSafe is a contract laboratory that develops assays and provides a range of testing services to help leading European biotech and pharmaceutical customers monitor for quality and compliance in the drug manufacturing process. The company employs thirty professionals and is based in Leiden, The Netherlands.

Martin D. Madaus, Millipore’s Chairman, CEO and President noted: “We are very pleased that MicroSafe is becoming part of Millipore. They have a loyal client base and the expertise that will help us expand the scope of service we offer to our biotech and pharmaceutical customers, particularly in the area of virus and mycoplasma testing. Their application knowledge will also help us accelerate development of products and systems for rapid process monitoring.”

Fathia Methnani, Managing Director of MicroSafe, B.V., commented: “With Millipore’s market presence in Europe and scientists and applications specialists in the field we will be able to bring our services to more clients and we’ll be able to expand those service offerings.” Ms. Methnani will continue to direct MicroSafe operations.

MicroSafe, with annual revenues of $4 million, has received GMP and GLP approvals and is currently expanding its capabilities to meet growing customer needs.

About Millipore

Millipore is a leading bioprocess and bioscience products and services company, organized into two divisions. The Bioprocess division offers solutions that optimize development and manufacturing of biologics. The Bioscience division provides high performance products and application insights that improve laboratory productivity. Millipore has a deep understanding of its customers’ research and manufacturing process needs, and offers reliable and innovative tools, technologies and services. The Company employs approximately 4,500 people worldwide and posted revenues of $883 million in 2004.

For additional information on Millipore Corporation, please visit its website at:

Forward Looking Statements:

The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Potential risks and uncertainties that could affect Millipore’s future operating results include, without limitation, foreign exchange rates; regulatory delay in the approval of new therapeutics and their ultimate commercial success; further consolidation of drug manufacturers; competitive factors such as new membrane technology; lack of availability of raw materials or component products on a timely basis; inventory risks due to shifts in market demand; change in product mix; conditions in the economy in general and in the bioscience and bioprocess markets in particular; potential environmental liabilities; the inability to utilize technology in current or planned products due to overriding rights by third parties; difficulties inherent in research and development activities; and the risk factors listed from time to time in Millipore’s filings with the SEC.
# # #

CONTACT: Millipore Corporation
Investor Contact:
Geoffrey Helliwell, 978/715-1041 or 800/225-3384
[email protected]
Media Contact:
Thomas Anderson, 978/715-1043 or 800/225-3384
[email protected]


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.